Molecular pattern of ductal pancreatic cancer

被引:43
作者
Sirivatanauksorn, V
Sirivatanauksorn, Y
Lemoine, NR [1 ]
机构
[1] Hammersmith Hosp, Imperial Coll, Sch Med,Mol Pathol Lab, Imperial Canc Res Fund,Mol Oncol Unit, London W12 0NN, England
[2] Hammersmith Hosp, Imperial Coll, Sch Med, Div Surg Anaesthet & Intens Care, London W12 0NN, England
关键词
pancreatic cancer; oncogene; tumour suppressor gene; growth factors; growth factor receptors;
D O I
10.1007/s004230050101
中图分类号
R61 [外科手术学];
学科分类号
摘要
Our understanding of the molecular pathology underlying the development and progression of ductal pancreatic cancer has been revolutionised during the last 5 years due to the spectacular development of novel molecular biological techniques. In the present article, we describe key molecular alterations of sporadic and inherited ductal pancreatic cancer. Overexpression of growth factors and growth factor receptors are present in a significant proportion of this tumour type. Mutation of the K-ras oncogene, and disruption of p53 or p16 tumour suppressor gene abrogates the control of the cyclin-dependent kinases (cdk) and retinoblastoma (Rb) gene pathway, causing continuous growth of the pancreatic tumour. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor beta signalling pathway. Lost or decreased expression of retinoid receptors and failure of telomerase activity may play a role in pancreatic carcinogenesis. Tumour-associated proteinases, matrix metalloproteinases and plasminogen activators are reported to be involved in pancreatic cancer invasion and metastasis. Furthermore, the cytogenetic changes in this cancer are summarised. This molecular pattern distinguishes pancreatic cancer from other epithelial rumours and represents a promising basis for the development of diagnostic and other clinical applications.
引用
收藏
页码:105 / 115
页数:11
相关论文
共 149 条
  • [1] MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES
    ALMOGUERA, C
    SHIBATA, D
    FORRESTER, K
    MARTIN, J
    ARNHEIM, N
    PERUCHO, M
    [J]. CELL, 1988, 53 (04) : 549 - 554
  • [2] BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206
  • [3] ABNORMALITIES OF THE P53 TUMOR SUPPRESSOR GENE IN HUMAN PANCREATIC-CANCER
    BARTON, CM
    STADDON, SL
    HUGHES, CM
    HALL, PA
    OSULLIVAN, C
    KLOPPEL, G
    THEIS, B
    RUSSELL, RCG
    NEOPTOLEMOS, J
    WILLIAMSON, RCN
    LANE, DP
    LEMOINE, NR
    [J]. BRITISH JOURNAL OF CANCER, 1991, 64 (06) : 1076 - 1082
  • [4] ABNORMALITIES OF THE RB1 AND DCC TUMOR-SUPPRESSOR GENES - UNCOMMON IN HUMAN PANCREATIC ADENOCARCINOMA
    BARTON, CM
    MCKIE, AB
    HOGG, A
    BIA, B
    ELIA, G
    PHILLIPS, SMA
    DING, SF
    LEMOINE, NR
    [J]. MOLECULAR CARCINOGENESIS, 1995, 13 (02) : 61 - 69
  • [5] PROGNOSTIC-SIGNIFICANCE OF K-RAS MUTATIONS IN COLORECTAL-CARCINOMA
    BENHATTAR, J
    LOSI, L
    CHAUBERT, P
    GIVEL, JC
    COSTA, J
    [J]. GASTROENTEROLOGY, 1993, 104 (04) : 1044 - 1048
  • [6] RETINOIDS IN CANCER PREVENTION AND THERAPY
    BOLLAG, W
    HOLDENER, EE
    [J]. ANNALS OF ONCOLOGY, 1992, 3 (07) : 513 - 526
  • [7] BOS JL, 1989, CANCER RES, V49, P4682
  • [8] Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO
  • [9] 2-J
  • [10] Expression of collagenase (MMPZ), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease
    Bramhall, SR
    Stamp, GWH
    Dunn, J
    Lemoine, NR
    Neoptolemos, JP
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (08) : 972 - 978